The effect of digoxin on exercise capacity and exercising cardiac function in cystic fibrosis.
The ability of digoxin to increase exercise capacity and stroke volume (SV) during exercise was evaluated in ten patients with cystic fibrosis (CF) ages 12 to 20 years with moderate to severe degrees of airway obstruction but no history of heart failure. A double-blind crossover trial of digoxin versus placebo was carried out. An evaluation of exercise performance was undertaken upon entry into the study, and after each of the one-week periods in which digoxin 0.25 mg/day or placebo was taken. Exercise testing consisted of a progressive exercise test on a cycle ergometer to measure maximum work capacity (Wmax) and a steady state test at 2/3 of the baseline Wmax. During the steady state test, the oxygen consumption and carbon dioxide production were measured and cardiac output (Q) was calculated by the indirect Fick (CO2) method. From Q and heart rate (HR), SV was derived. After digoxin, Wmax was unchanged. On steady state exercise HR was unchanged, but there was a slight but significant fall in Q due to a fall in SV. The decrease in SV was associated with exercising hypoxemia. We conclude that digoxin did not increase exercise capacity or improve exercising cardiac function in patients with moderate to severe airway obstruction due to CF.
D000293:Adolescent; D000328:Adult; D001784:Blood Gas Analysis; D002302:Cardiac Output / Q000187:drug effects; D002648:Child; D003550:Cystic Fibrosis / Q000503:physiopathology*; D004077:Digoxin / Q000494:pharmacology*; D004311:Double-Blind Method; D006321:Heart / Q000187:drug effects* / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D005082:Physical Exertion / Q000187:drug effects*; D012129:Respiratory Function Tests; D013318:Stroke Volume / Q000187:drug effects
D004077:Digoxin